Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eltanexor (Primary) ; Abiraterone; Cedazuridine; Decitabine; Dexamethasone
  • Indications Adenocarcinoma; Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Karyopharm Therapeutics

    • Most Recent Events

    • 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record
    • 05 Mar 2024 Planned End Date changed from 31 Aug 2024 to 31 Dec 2024.
    • 30 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top